Landscapes / Companies
GE Healthcare not checked
FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
3 approved
2 in Phase 3
Drugs
5
in active trials · 17 in all
Trials
5 active
17 since 2021
Drugs5
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Regadenosonnot checked |
Adenosine receptor agonist |
Astellas |
Approved | Dec 2026Phase 1/2 trial completes | |
| Next date | Dec 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Myocardial Ischemia, Coronary Artery Disease | ||||
| Open drug page | |||||
— |
Approved in the EU | 25 Feb 2027Phase 2 trial completes | |||
| Next date | 25 Feb 2027 · Phase 2 trial completes | ||||
| Also tested for | Cognitive Dysfunction | ||||
| Open drug page | |||||
— |
Approved | — | |||
| Also tested for | Metastatic Breast Cancer | ||||
| Open drug page | |||||
— |
Phase 2/3 | 30 Nov 2027Phase 2/3 trial completes | |||
| Next date | 30 Nov 2027 · Phase 2/3 trial completes | ||||
| Also tested for | Known or Highly Suspected Central Nervous System (CNS) Lesion, Known or Highly Suspected Body (Excluding CNS) Lesion | ||||
| Open drug page | |||||
— |
Phase 2/3 | Jun 2029Phase 2/3 trial completes | |||
| Next date | Jun 2029 · Phase 2/3 trial completes | ||||
| Also tested for | Colorectal Cancer, Gastric Cancers and 2 more | ||||
| Open drug page | |||||
About
- No active trial
- 12 other drugs
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 Industry-sponsored drug trials since 2021